Boston researchers test new epilepsy treatment; Pfizer homes in on Icagen buyout;

 @FierceBiotech: The Latest Sirtuin Controversy. Article Read the excellent article by @Dereklowe. | Follow @FierceBiotech

 @JohnCFierce: In case you missed it: Enzon is chopping its workforce in half. Article | Follow @JohnCFierce

 @RyanMFierce: Anyone really surprised $AZ is going with partner over M&A strategy in China, though? Not aware of many biotechs there ripe for takeovers. | Follow @RyanMFierce

 @MaureenFierce: RT @Loftus: Merck rotavirus vaccine cut hospitalizations, spending, according to CDC. Report | Follow @MaureenFierce

 @FierceMedDev: More exec moves at AngioDynamics: Scott Solano to Depart AngioDynamics. Release | Follow @FierceMedDev

> Researchers at Children's Hospital Boston are advancing a magnetic brain stimulation therapy for treating epilepsy into clinical development. Blog

> Gilead Sciences ($GILD) said it has won the backing of an EMA committee for its bid to gain approval of its HIV therapy Eviplera, which combines the firm's Truvada with Tibotec's Edurant in a single tablet taken once a day. Release

> Pfizer ($PFE), the world's largest drugmaker, is making progress in its pursuit to acquire Icagen. Report

> Illinois Gov. Pat Quinn has inked a pact with officials in China that he hopes will strengthen ties between biotechs in his state and those in the Asian country. Report

> Waltham, MA-based ImmunoGen ($IMGN) plans to usher into initial clinical trials one of its antibodies linked to a cancer-killing agent, IMGN529, to combat non-Hodgkin's lymphoma. Item

Pharma News

@FiercePharma: CHMP on Multaq: Use after considering alternatives, and only in certain AF patients. For them, benefits > risks $SNY. Item | Follow @FiercePharma

> NHS overspent on modern insulins, BMJ suggests. Article

> Xarelto tees up big new European approval. Story

> GSK chief: What the world needs is 'cleverer' drug pricing. Item

> EMA calls for limits on Sanofi's Multaq. Report

And Finally... a top U.S. health official says that there are now more than 300 National Cancer Institute-supported clinical trials that involve a cancer drug in scarce supply. Article

Suggested Articles

Biogen will develop a gene therapy with the goal of preserving and possibly restoring vision in patients with PRPF31-mutated retinitis pigmentosa.

A month after moving its COVID-19 antibody cocktail into human trials, Regeneron is testing the drug's ability to ward off COVID-19 infection.

Short reports are nothing new, but the aggressive “I’m coming after you” PR from Applied Therapeutics certainly is.